REGN - Regeneron Pharmaceuticals Full Takeover Company Value

Brandmark of Regeneron Corp (REGN)

This price chart on GURU.Markets for Regeneron Pharmaceuticals (REGN) shows an Enterprise Value of 90232.71. Regeneron Pharmaceuticals (REGN) generates revenue from exclusive treatments for orphan diseases, leveraging patent protection to maintain significant pricing power. Growth is based on protecting core products and actively seeking new antibodies in immunology. Meanwhile, substantial cash reserves and profits from ophthalmology drugs mitigate the risks of losing exclusive rights.

Regeneron Pharmaceuticals, Inc. (REGN) - Enterprise Value from 11/23/2025 to 10/31/2026

Regeneron Pharmaceuticals (REGN) - metric breakdowns and financial figures

- market value and analyst target forecast:
Market Price Regeneron Pharmaceuticals, Inc.|REGN - Analyst Consensus Forecast
- market capitalization statistics:
Market Capitalization Regeneron|REGN - Total Company Value
- company book value details:
Equity per Share Regeneron|REGN - Book Capitalization|Market Value to Book Value regeneron.com|REGN - Company Total Assets
- debt level and financial liquidity data:
Debt to Capital Regeneron Pharmaceuticals|REGN - Long-Term Debt to Capital|Short-Term Debt to Capital regeneron.com|REGN - Company Debts|Debt to Net Assets Ratio Regeneron|REGN - Company Long-Term Liabilities|Amount of Current Liabilities Regeneron|Intermediate Coverage Ratio regeneron.com
- earnings and valuation multiples indicators:
REGN - Net Profit
Analysis of all company metrics:Regeneron Pharmaceuticals, Inc.
Manufactured product of Regeneron Pharmaceuticals

This indicator reflects the total enterprise value, combining market capitalization with net debt to determine the actual cost of a full asset buyout. The price action of the enterprise value confirms the resilience of Regeneron Pharmaceuticals (REGN), as a diversified portfolio of oncology and cardiology drugs, supplemented by a broad pipeline, minimizes patent risks and justifies the company's current valuation from a strategic investor's perspective.

Competitor analysis for Regeneron Pharmaceuticals

iRhythm Technologies, Inc. (IRTC) - Total Enterprise Value|Lantheus Medical Imaging - Enterprise Value|Full Takeover Company Value Mineralys Corp (MLYS)|HeartFlow Medical (HTFL) - Total Company Value|Business Value KMTS|ESPR (Esperion) - Enterprise Value|AMRN: Value Adjusted for Debt and Cash|Enterprise Value AVR|TNYA - Total Enterprise Value|Enterprise Value CVRX (CVRx, Inc.)|Enterprise Value milestonepharma.com MIST|CRDL - Total Company Value|Value Adjusted for Debt and Cash BEAT (HeartBeam Inc)|TENX (Tenax Therapeutics, Inc) - Real Price to Acquire Entire Company|ADGM: Aggregate Business Value|Total Company Value BioCardia, Inc.|VTAK: Value Adjusted for Debt and Cash|Enterprise Value ABIO|ACST - Total Enterprise Value|Enterprise Value AVTE (Aerovate)|Full Takeover Company Value Verve Therapeutics Inc.|Windtree - Enterprise Value